Pharmaceuticals News and Research

RSS

Decade Sunshine, 3SBio enter Merger Agreement

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has entered into an agreement and plan of merger with Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, and Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent.

10 Feb 2013

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

UT Southwestern Medical Center scientists have synthesized a peptide that shows potential for pharmaceutical development into agents for treating infections, neurodegenerative disorders, and cancer through an ability to induce a cell-recycling process called autophagy.

10 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Taro, Sun Pharma mutually agree to terminate merger agreement

Taro Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. announced today that they have mutually agreed to terminate their merger agreement, announced in August 2012, pursuant to which all shareholders of Taro would have received a cash payment of $39.50 per share upon the closing of the merger.

10 Feb 2013

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole, in patients with previous cerebrovascular disease.

10 Feb 2013

Weekend reading: Mental health discrimination; A doctor faces hard questions; Long-term outlook for health care jobs

"When I had cancer, I got cards and flowers," Karen Kangas' sign reads. "When I was diagnosed with bipolar disorder, I got no cards and a pink slip." A picture of Kangas holding the sign hangs in the state Capitol complex, part of an exhibit called "Discrimination: A Roadblock to Recovery."

9 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Conference attendees express concern over growing burden of NCDs

Inter Press Service reports on "a conference organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on World Cancer Day [February 4] in Geneva," during which experts warned about the growing burden of non-communicable diseases (NCDs) -- "cancer, heart disease, diabetes and chronic respiratory diseases, among others" -- especially in low- and middle-income countries.

7 Feb 2013

Cantor calls for repeal of medical device tax; Bipartisan Senate bill seeks to end generic drug delays

In a speech, the House majority leader criticized the health law but focused his attention on the overhaul's taxes. Meanwhile, the Senate measure would prohibit companies that make brand-name drugs from paying generic manufacturers to keep their products off the market.

7 Feb 2013

Innovative drug discovery in Europe supported by Bayer

Bayer HealthCare initiated and will coordinate a newly founded pan-European consortium, named European Lead Factory, which has been launched to enhance early drug discovery addressing the need for innovative drugs. The new five-year project will create an exceptional small molecule library collection allowing drug discovery on innovative and promising targets from pharma companies and academia.

7 Feb 2013

More than £6M funding awarded to enhance development of biopharmaceuticals

More than £6M of funding has been awarded to enhance the development of biopharmaceuticals. In total £6.5M will fund 12 projects to deliver commercially important results, such as industrial-scale production of antibodies, stem cell preservation at room temperature, biopharmaceutical production using microbes and commercial scale stem cell therapy.

6 Feb 2013

CDC, State Department, World Bank should lead fight against fake, substandard TB drugs

"Thanks to billions of dollars spent on diagnosis and treatment of tuberculosis (TB) over the past decade, deaths and infections are slowly declining," but "fake and poorly made antibiotics are being widely used to treat tuberculosis," according to a study "to be published Tuesday in the International Journal of Tuberculosis and Lung Disease," Roger Bate, a resident scholar at the American Enterprise Institute and an author of the study, writes in a New York Times opinion piece.

6 Feb 2013

Non-coding RNA MALAT1 influences lung cancer metastasis

The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides.

6 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.

5 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Viral conjunctivitis: potential new treatment

Viral conjunctivitis is a highly contagious infection, often causing major ophthalmic epidemics. There is no approved acute treatment currently approved by the FDA for viral conjunctivitis. A safe broad-spectrum antiviral agent is needed to treat this unmet medical need.

5 Feb 2013

Restricting gifts in medical school influences future prescribing behavior

US physicians who attended a medical school with a policy restricting acceptance of gifts from pharmaceutical companies are less likely to prescribe newly marketed drugs than physicians who were not exposed to such restrictions during training, according to research published in the BMJ.

5 Feb 2013

BD first quarter revenues increase 3.7% to $1.90 billion

BD, a leading global medical technology company, today reported quarterly revenues of $1.90 billion for the first fiscal quarter ended December 31, 2012, representing an increase of 3.7 percent from the prior-year period, or 5.2 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 5 Feb 2013

Pharmaceuticals News and Research

Decade Sunshine, 3SBio enter Merger Agreement

Tat-beclin 1 shows promise against infections, neurodegenerative disorders and cancer

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Taro, Sun Pharma mutually agree to terminate merger agreement

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

Weekend reading: Mental health discrimination; A doctor faces hard questions; Long-term outlook for health care jobs

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Conference attendees express concern over growing burden of NCDs

Cantor calls for repeal of medical device tax; Bipartisan Senate bill seeks to end generic drug delays

Innovative drug discovery in Europe supported by Bayer

More than £6M funding awarded to enhance development of biopharmaceuticals

CDC, State Department, World Bank should lead fight against fake, substandard TB drugs

Non-coding RNA MALAT1 influences lung cancer metastasis

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Viral conjunctivitis: potential new treatment

Restricting gifts in medical school influences future prescribing behavior

BD first quarter revenues increase 3.7% to $1.90 billion

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence